By Sahil Pandey July 22 (Reuters) - Repligen Corp said on Wednesday it would buy BioLife Solutions in a cash-and-stock deal ...

Why Medical Products Maker Repligen May Be A Potential Buy Repligen (NASDAQ:RGEN) said it has signed a definitive agreement ...

Fast-tracks Repligen’s leadership and customer solution offering in high-growth cell therapy market by adding BioLife’s differentiated, high-margin recurring revenue business BioLife stockholders to ...

BioLife Solutions, a Bothell, Wash.-based company developing tools for cell and gene therapy, is being acquired for $1.5 ...

Life sciences equipment and consumable manufacturer Repligen has reached a deal to buy cell therapy specialist BioLife ...

Repligen Corporation has finalized a definitive agreement to acquire BioLife Solutions, aiming to significantly expand its ...

Repligen (RGEN) stock dropped 5.84% after unveiling a $1.5B deal to acquire BioLife Solutions (BLFS) at $31/share with cash ...

Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of BioLife Solutions, Inc. (NasdaqCM: BLFS) to Repligen Corporation (NasdaqGS: RGEN). Under the ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

BOTHELL, Wash., March 2, 2020 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of best-in-class bioproduction tools for cell and gene therapies, today announced ...